Audentes Therapeutics Inc (NASDAQ:BOLD) VP Suyash Prasad sold 8,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Audentes Therapeutics Inc (NASDAQ BOLD) traded down $0.29 during trading on Tuesday, hitting $27.38. 130,739 shares of the stock traded hands, compared to its average volume of 148,087. Audentes Therapeutics Inc has a 1 year low of $13.90 and a 1 year high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.88). research analysts forecast that Audentes Therapeutics Inc will post -3.52 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. TD Asset Management Inc. grew its holdings in shares of Audentes Therapeutics by 2.4% in the second quarter. TD Asset Management Inc. now owns 25,280 shares of the biotechnology company’s stock worth $484,000 after purchasing an additional 598 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Audentes Therapeutics by 27.1% in the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 3,324 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Audentes Therapeutics by 22.6% in the first quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 4,310 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Audentes Therapeutics by 36.2% in the first quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 5,009 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Audentes Therapeutics in the third quarter worth approximately $143,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

BOLD has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Leerink Swann reiterated an “outperform” rating and set a $29.00 price target (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. William Blair initiated coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.29.

COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics Inc (BOLD) VP Suyash Prasad Sells 8,000 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/05/audentes-therapeutics-inc-bold-vp-suyash-prasad-sells-8000-shares.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.